510(K) SUMMARY

Agfa Skintell – Optical Coherence Tomography (OCT) System

Common Name: Optical Coherence Tomography (OCT) System
Classification Name: System, Imaging, Optical Coherence Tomography (OCT)
Regulatory Classification: 21 CFR 892.1560
Product Code: NQQ
Proprietary Name: Skintell
Agfa HealthCare N.V.
Septestraat 27
B-2640 Mortsel
Belgium
Contact: Koen Vervoort, Prepared: September 6, 2013
Telephone: +32-34444-7368

A. LEGALLY MARKETED PREDICATE DEVICES

This is a 510(k) for Agfa’s Skintell which is an optical coherence tomography (OCT) imaging device. It is substantially equivalent to the system with Michelson Diagnostics VivoSight Topical OCT System (K093520).

B. DEVICE DESCRIPTION

Agfa’s Skintell is an optical coherence tomography imaging device (OCT) weighing approximately 105kg. It is used to create images of non-open wounded human skin and the corresponding close-to-surface tissue.

Skintell offers users the following functions:
- volume and cross-sectional imaging
- high resolution rendering of structures
- geometrical length- measurements

C. INTENDED USE

Agfa’s Skintell is an Optical Coherence Tomography (OCT) system indicated for use in two-dimensional, cross-sectional, real-time imaging of external tissues of human body.

D. SUBSTANTIAL EQUIVALENCE SUMMARY

Agfa’s Skintell has an Indications For Use statement identical to the statement for the predicate device, K093520. Intended uses are the same. The devices have the same technological characteristics. Descriptive characteristics and performance data are adequate to ensure equivalence.
Differences in devices do not alter the intended therapeutic/diagnostic effect.

<table>
<thead>
<tr>
<th>PRODUCT COMPARISON TABLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skintell</td>
</tr>
<tr>
<td>(New Device)</td>
</tr>
<tr>
<td>Michelson VivoSight Topical OCT</td>
</tr>
<tr>
<td>(PREDICATE-K093520)</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Network Connectivity</strong></td>
</tr>
<tr>
<td><strong>Scanning Technology</strong></td>
</tr>
<tr>
<td><strong>Laser Center Wavelength</strong></td>
</tr>
<tr>
<td><strong>Optical Resolution</strong></td>
</tr>
<tr>
<td><strong>Lateral Scanning Range</strong></td>
</tr>
<tr>
<td><strong>Image Acquisition Speed</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Image Depth</strong></td>
</tr>
<tr>
<td><strong>Power Supply</strong></td>
</tr>
<tr>
<td><strong>Weight</strong></td>
</tr>
<tr>
<td><strong>Image Presentation</strong></td>
</tr>
<tr>
<td><strong>Image Formats</strong></td>
</tr>
<tr>
<td><strong>Operating System</strong></td>
</tr>
<tr>
<td><strong>Display System</strong></td>
</tr>
</tbody>
</table>

E. TECHNOLOGICAL CHARACTERISTICS

Agfa’s Skintell is an optical coherence tomography (OCT) imaging device. Principles of operation and technological characteristics of the new and predicate device are largely the same as other optical coherence tomography systems.

The Agfa Skintell system is identical to the Michelson Diagnostic VivoSight Topical OCT system (K093520) with the exception of the following:

- Optical resolution of 3 μm lateral and axial
- Scanning range of 1.8 mm x 1.5 mm (enface)
- Image depth of up to 1.0 mm

The differences of the devices are optical resolution of < 7.5 μm for lateral and < 5 μm for axial of the Michelson Topical OCT device (K093520) is worse with respect to the resolution 3 μm for both lateral and axial of the Agfa Skintell device. However, the penetration depth of the Michelson Topical OCT device (K093520) is about twice of the penetration depth of the Agfa Skintell device. Even though the Michelson device is able to scan images at a deeper depth, the depth resolution declines while the Agfa Skintell images are clearly separable. Therefore, Agfa’s Skintell device produces sharper and clearer images than the Michelson device even
though they are acquired at a shallower depth. Furthermore, this depth of 1.0mm in the epidermal/dermal junction in most cases is where many of the significant changes/structures/lesions are present. The Michelson Topical OCT device (K093520) allows for a wider scanning range of 5mm x 5mm than the Agfa Skintell device which is 1.8mm x 1.5mm (enface). However, the Skintell probe is movable allowing the smaller field of view (scanning range) to be moved to the required section where all the area can be viewed. However, these differences are minor and would not be expected to impact safety and effectiveness.

F. TESTING

The device has completed verification and validation testing to confirm it meets specifications and operates as planned. Tests included standard workflow tests, biocompatibility tests, and image quality evaluations with external and internal experts comparing Agfa’s Skintell device to the Michelson Diagnostics VivoSight Topical OCT (K093520) predicate device.

Images were taken using both the slice and enface modes of the Skintell device and analyzed histopathologically. Typical patterns of normal skin as well as typical patterns of lesions itself visible on the standard HE stained histopathology section can be linked to image patterns visible in the slice- and enface-images of the Skintell device. Thus, Skintell offers the possibility to visualize skin-structures in-vivo.

The product, manufacturing and development processes have been shown to conform to product safety, radiology, and imaging standards including:

PRODUCT STANDARDS

- EN 1041:2008 Information Supplied by the Manufacturers of Medical Devices

QUALITY MANAGEMENT STANDARDS

- ISO 14971:2007 Application of Risk Management to Medical Devices
- ISO 13485:2003 Medical Devices - Quality Management Systems - Requirements For Regulatory purposes
- ISO10993-10: 2010 - Biocompatibility: Tests for Irritation and Skin Sensitation

NOTE: Agfa recognizes two other standards (AOL 2008 and IEC60601-2-37) associated with
the product classification NQQ; however, Agfa does not feel these standards apply to Skintell and Michelson’s VivoSight devices. Please refer to Exhibit 8 for the explanation of this determination.

G. CONCLUSIONS

Agfa’s Skintell device has an Indications For Use statement that is identical to the statement for the predicate device, K093520. Intended uses are the same.

Agfa’s Skintell system is substantially equivalent to Michelson Diagnostic’s VivoSight Topical OCT System (K093520) in that it uses the same technology to create images of non-open wounded human skin and the corresponding close-to-surface tissue. Both Agfa’s Skintell device and Michelson Diagnostics VivoSight Topical OCT device (K093520) use the same components including, a non-invasive probe, PC with monitor, and foot pedal. Both the new device and the predicate device weigh 105kg and use a comparable Windows operating system. Agfa’s Skintell system and Michelson Diagnostic’s VivoSight Topical OCT system (K093520) both offer volume and cross-sectional imaging, high resolution, and geometric length measurements.

This 510(k) has demonstrated Substantial Equivalence as defined and understood in the Federal Food Drug and Cosmetic Act and various guidance documents issued by the Center for Devices and Radiological Health.
March 3, 2014

Agfa HealthCare N.V.
% Ms. ShaeAnn Cavanagh
AGFA Healthcare
10 South Academy Street
Greenville, South Carolina 29601

Re: K132800
 Trade/Device Name: Agfa Healthcare N.V Skintel
 Regulation Number: 21 CFR 892.1560
 Regulation Name: Ultrasonic pulsed echo imaging system
 Regulatory Class: Class II
 Product Code: NQQ
 Dated: January 17, 2014
 Received: January 22, 2014

Dear Ms. Cavanagh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Felipe Aguel

for

Binita S. Ashar, M.D., M.B.A., F.A.C.S.
Acting Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure
Indications for Use

510(k) Number (if known)
k132800

Device Name
Agfa Healthcare N.V Skintell

Indications for Use (Describe)
Agfa’s Skintell is an Optical Coherence Tomography (OCT) system indicated for use in two-dimensional, cross-sectional, real-time imaging of external tissues of human body.

Type of Use (Select one or both, as applicable)

☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Felipe Aguel Date: 2014.03.03 10:25:31 -05'00'

FORM FDA 3881 (1/14)